PH12015502802A1 - Formulation comprising a hypolipidemic agent - Google Patents

Formulation comprising a hypolipidemic agent

Info

Publication number
PH12015502802A1
PH12015502802A1 PH12015502802A PH12015502802A PH12015502802A1 PH 12015502802 A1 PH12015502802 A1 PH 12015502802A1 PH 12015502802 A PH12015502802 A PH 12015502802A PH 12015502802 A PH12015502802 A PH 12015502802A PH 12015502802 A1 PH12015502802 A1 PH 12015502802A1
Authority
PH
Philippines
Prior art keywords
formula
formulation
hypolipidemic agent
compounds
present
Prior art date
Application number
PH12015502802A
Other languages
English (en)
Inventor
Jitendre D Patel
Davadra Prakash
Patel Snehal
Sheikh Shafiq
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Publication of PH12015502802A1 publication Critical patent/PH12015502802A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PH12015502802A 2013-07-25 2015-12-17 Formulation comprising a hypolipidemic agent PH12015502802A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2470MU2013 IN2013MU02470A (OSRAM) 2013-07-25 2013-07-25
PCT/IN2014/000489 WO2015011730A1 (en) 2013-07-25 2014-07-24 Formulation comprising a hypolipidemic agent

Publications (1)

Publication Number Publication Date
PH12015502802A1 true PH12015502802A1 (en) 2016-03-14

Family

ID=51787141

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12015502802A PH12015502802A1 (en) 2013-07-25 2015-12-17 Formulation comprising a hypolipidemic agent

Country Status (21)

Country Link
US (2) US9610277B2 (OSRAM)
EP (1) EP3024446A1 (OSRAM)
JP (1) JP2016523895A (OSRAM)
KR (1) KR101786843B1 (OSRAM)
CN (1) CN105407873A (OSRAM)
AP (1) AP2015008876A0 (OSRAM)
AR (1) AR097067A1 (OSRAM)
AU (1) AU2014294548B2 (OSRAM)
BR (1) BR112015031878A2 (OSRAM)
CA (1) CA2917923A1 (OSRAM)
EA (1) EA201690072A1 (OSRAM)
HK (1) HK1219222A1 (OSRAM)
IN (1) IN2013MU02470A (OSRAM)
MA (1) MA38865A1 (OSRAM)
MX (1) MX374628B (OSRAM)
NZ (1) NZ714558A (OSRAM)
PH (1) PH12015502802A1 (OSRAM)
SG (1) SG11201509798PA (OSRAM)
TW (1) TW201545773A (OSRAM)
WO (1) WO2015011730A1 (OSRAM)
ZA (1) ZA201508682B (OSRAM)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101427486B (zh) 2006-05-23 2013-06-19 英特尔公司 具有定向天线和一个或多个毫米波反射器的毫米波通信系统
SI2670486T1 (sl) 2011-01-31 2016-09-30 Cadila Healthcare Limited Zydus Tower Satellite Cross Roads Zdravljenje lipodistrofije
SG11201506218UA (en) 2013-04-22 2015-09-29 Cadila Healthcare Ltd A novel composition for nonalcoholic fatty liver disease (nafld)
ES2889916T3 (es) 2013-05-30 2022-01-14 Cadila Healthcare Ltd Un procedimiento para la preparación de pirroles con actividades hipolipidémicas e hipocolesterémicas
TW201513857A (zh) 2013-07-05 2015-04-16 Cadila Healthcare Ltd 協同性組成物
IN2013MU02470A (OSRAM) 2013-07-25 2015-06-26 Cadila Healthcare Ltd
IN2013MU02905A (OSRAM) 2013-09-06 2015-07-03 Cadila Healthcare Ltd
WO2017064635A2 (en) 2015-10-14 2017-04-20 Cadila Healthcare Limited Pyrrole compound, compositions and process for preparation thereof
KR101913830B1 (ko) * 2016-12-05 2018-10-31 주식회사 코쿤디자인 기능성 led 어셈블리를 이용한 디스플레이 장치
US20180243263A1 (en) 2016-12-09 2018-08-30 Cadila Healthcare Ltd. Treatment for primary biliary cholangitis
WO2020165782A1 (en) * 2019-02-13 2020-08-20 Cadila Healthcare Limited Treatment for polycystic ovarian syndrome (pcos)
WO2020183379A1 (en) * 2019-03-11 2020-09-17 Cadila Healthcare Limited Novel salts, crystalline forms and premix of hypolipidemic agent

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
DK149080C (da) 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
US5030447A (en) * 1988-03-31 1991-07-09 E. R. Squibb & Sons, Inc. Pharmaceutical compositions having good stability
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
AU678974B2 (en) 1992-07-03 1997-06-19 Smithkline Beecham Plc Heterocyclic compounds as pharmaceutical
GB9225386D0 (en) 1992-12-04 1993-01-27 Smithkline Beecham Plc Novel compounds
US5387613A (en) 1993-07-23 1995-02-07 Ribogene, Inc. Treatment of tachyarrhythmias of supraventricular origin
GB9326171D0 (en) 1993-12-22 1994-02-23 Smithkline Beecham Plc Novel compounds
BR9508468A (pt) 1994-07-29 1997-11-25 Smithkline Beecham Plc Composto processo para a preparação do mesmo composição farmacéutica processos para o tratamento e/ou profilaxia de hiperglicemia em um mamifero humano ou não humano e para o tratamento de hiperlípidemia hipertensão doença cardiovascular alguns distúrbios de alimentação o tratamento e/ou profilaxia de doença renal a prevenção revers o estabilização ou retardo da progressão de microalbuminuria em um mamifero humano ou não humano uso do composto e composto intermediário
BR9608040B1 (pt) 1995-04-28 2010-02-23 composto taxàide pentacÍclico.
GB9600464D0 (en) 1996-01-09 1996-03-13 Smithkline Beecham Plc Novel method
GB9606805D0 (en) 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
AU1198699A (en) 1997-10-27 1999-04-23 Dr. Reddy's Research Foundation Novel heterocyclic compounds and their use in medicine, process for their reparation and pharmaceutical compositions containing them
WO1999019313A1 (en) 1997-10-27 1999-04-22 Dr. Reddy's Research Foundation Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
WO1999020614A1 (en) 1998-05-27 1999-04-29 Dr. Reddy's Research Foundation Bicyclic compounds, process for their preparation and pharmaceutical compositions containing them
AU1120599A (en) 1998-04-23 1999-03-08 Dr. Reddy's Research Foundation New heterocyclic compounds and their use in medicine, process for their reparation and pharmaceutical compositions containing them
AU6325799A (en) 1998-10-21 2000-05-08 Dr. Reddy's Research Foundation New compounds, their preparation and use
AU6325899A (en) 1998-10-21 2000-05-08 Dr. Reddy's Research Foundation New compounds, their preparation and use
JP2002527516A (ja) 1998-10-21 2002-08-27 ノボ ノルディスク アクティーゼルスカブ 新規化合物、それらの製造及び使用
CO5150173A1 (es) 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
OA12162A (en) 2000-01-19 2006-05-08 Cadila Healthcare Ltd Novel compounds having hypolipedemic, hypocholesteremic activities, process for their preparation and pharmaceutical compositions containing them.
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
WO2002024625A2 (en) 2000-09-22 2002-03-28 Dr. Reddy's Research Foundation Process for the preparation of 3-aryl-2-hydroxy propanoic acid derivatives
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
US6987123B2 (en) 2001-07-26 2006-01-17 Cadila Healthcare Limited Heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
JP4745616B2 (ja) * 2003-02-26 2011-08-10 武田薬品工業株式会社 安定化されたイミダゾール誘導体含有医薬組成物、イミダゾール誘導体の安定化方法
WO2005031335A1 (ja) 2003-09-26 2005-04-07 Mitsubishi Rayon Co., Ltd. 電気泳動装置および電気泳動法並びにそれを用いた生体関連物質の検出方法
CN102140090A (zh) 2004-03-15 2011-08-03 武田药品工业株式会社 二肽基肽酶抑制剂
AU2007218596C1 (en) * 2006-02-22 2012-07-26 Eisai R & D Management Co., Ltd. Stabilized pharmaceutical composition
US20090196923A1 (en) 2006-04-26 2009-08-06 Jayanta Kumar Mandal Controlled release formulation comprising anti-epileptic drugs
JP5424571B2 (ja) * 2007-04-12 2014-02-26 協和発酵キリン株式会社 トピラマート含有固形製剤
BR112012012815B8 (pt) 2009-11-26 2021-05-25 Genfit uso de um composto selecionado de 1-[4-metil-tio-fenil]-3-[3,5-dimetil-4-carbóxi-dimetil-metilóxi-fenil]prop-2-en-1-ona e ácido 2-[2,6-dimetil-4-[3-[4-(metil-tio)fenil]-3-oxo-propil]fenóxi]-2-metilpropanóico
AU2011316565A1 (en) * 2010-10-12 2013-05-02 Cerecor Inc. Antitussive compositions comprising memantine
SI2670486T1 (sl) * 2011-01-31 2016-09-30 Cadila Healthcare Limited Zydus Tower Satellite Cross Roads Zdravljenje lipodistrofije
SG11201506218UA (en) * 2013-04-22 2015-09-29 Cadila Healthcare Ltd A novel composition for nonalcoholic fatty liver disease (nafld)
ES2889916T3 (es) 2013-05-30 2022-01-14 Cadila Healthcare Ltd Un procedimiento para la preparación de pirroles con actividades hipolipidémicas e hipocolesterémicas
TW201513857A (zh) 2013-07-05 2015-04-16 Cadila Healthcare Ltd 協同性組成物
IN2013MU02470A (OSRAM) 2013-07-25 2015-06-26 Cadila Healthcare Ltd
IN2013MU02828A (OSRAM) 2013-08-29 2015-07-03 Cadila Healthcare Ltd
IN2013MU02905A (OSRAM) 2013-09-06 2015-07-03 Cadila Healthcare Ltd

Also Published As

Publication number Publication date
US10098868B2 (en) 2018-10-16
EP3024446A1 (en) 2016-06-01
HK1219222A1 (zh) 2017-03-31
JP2016523895A (ja) 2016-08-12
AU2014294548B2 (en) 2017-08-10
NZ714558A (en) 2017-02-24
MX2015016971A (es) 2016-04-25
TW201545773A (zh) 2015-12-16
BR112015031878A2 (pt) 2017-07-25
EA201690072A1 (ru) 2016-06-30
MA38865A1 (fr) 2017-12-29
WO2015011730A1 (en) 2015-01-29
AU2014294548A1 (en) 2015-12-17
CA2917923A1 (en) 2015-01-29
US20160136131A1 (en) 2016-05-19
KR101786843B1 (ko) 2017-10-18
US20170266158A1 (en) 2017-09-21
SG11201509798PA (en) 2016-02-26
ZA201508682B (en) 2017-03-29
US9610277B2 (en) 2017-04-04
IN2013MU02470A (OSRAM) 2015-06-26
KR20160013150A (ko) 2016-02-03
AR097067A1 (es) 2016-02-17
MX374628B (es) 2025-03-06
AP2015008876A0 (en) 2015-11-30
CN105407873A (zh) 2016-03-16

Similar Documents

Publication Publication Date Title
PH12015502802A1 (en) Formulation comprising a hypolipidemic agent
NZ716840A (en) Combination formulation of two antiviral compounds
PH12018502747A1 (en) Boronic acid derivatives and therapeutic uses thereof
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
MX2015008628A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
CA2875877C (en) Syk inhibitors
MY176814A (en) Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis
MX2011010311A (es) Formulaciones farmaceuticas que comprenden derivados de nitrocatecol y metodos para hacer las mismas.
BR112015021983A2 (pt) compostos heterocíclicos e usos dos mesmos
EA201270216A1 (ru) Фармацевтический состав
BR112015000229A2 (pt) formulações aquosas estáveis de etanercept
PH12015501752A1 (en) Substituted bisphenyl butanoic phosphonic acid derivatives as nep inhibitors
EA201792597A3 (ru) Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения
WO2013177534A3 (en) New salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof
MX390763B (es) Compuestos de tetraciclina
PH12016500577A1 (en) Piperazine derivatives and the use thereof as medicament
WO2014166836A8 (en) Growth hormone compound formulation
IN2013MU02442A (OSRAM)
TN2015000524A1 (en) Pharmaceutical compositions
SA112330437B1 (ar) تركيبات دوائية محتوية على عامل منوم او مخدر وطريقة تحضيرها
TN2013000137A1 (en) Pharmaceutical compositions containing a dgat 1 inhibitor